After rancorous threats and a clinical hold, Applied Therapeutics is set to resume pediatric galactosemia study
After an anonymous report raised red flags over Applied Therapeutics’ integrity in July, saying the company “cherry picked” data and ostensibly prompting a short attack, the biotech accused the authors of the report of fraud and threatened legal action. Then, a month later, the FDA indicated it also had concerns over its lead galactosemia program, slapping a clinical hold on a study testing their candidate in children.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.